Damon DeSantis (INBP) reports 1,363,685-share gift transfer

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

INTEGRATED BIOPHARMA INC director Damon DeSantis reported bona fide gift transfers involving 1,363,685 shares of Common Stock. The transactions, coded as gifts, were recorded at a price of $0.00 per share and are held indirectly through CDDS 2.0, LLC.

Footnotes state that 1,356,293 shares were transferred from CD Financial, LLC and 7,392 shares from the Carl DeSantis Revocable Trust to CDDS 2.0, LLC, which is controlled by DeSantis. Following these transfers, he indirectly holds 1,363,685 shares of the company’s common stock.

Insider Trade Summary

1,363,685 shares gifted

Mixed 2 txns

Insider DeSantis Damon

Role Director

Type	Security	Shares	Price	Value
Gift	Common Stock	1,356,293	$0.00	--
Gift	Common Stock	7,392	$0.00	--

Holdings After Transaction: Common Stock — 1,356,293 shares (Indirect, By CDDS 2.0, LLC)

Footnotes (1)

Represents 1,356,293 shares of Common Stock transferred from CD Financial, LLC, a Florida limited liability company, to CDDS 2.0, LLC, a Florida limited liability company controlled by the Reporting Person. Represents 7,392 shares of Common Stock transferred from the Carl DeSantis Revocable Trust to CDDS 2.0, LLC, a Florida limited liability company controlled by the Reporting Person.

Form 4 Insider Transactions: What Each Field Means →

03/25/2026 - 03:39 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeSantis Damon

(Last)

(First)

(Middle)

109 SE 5TH AVENUE

SECOND FLOOR

(Street)

DELRAY BEACH

FLORIDA

33483

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTEGRATED BIOPHARMA INC [ INBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/24/2026		G⁽¹⁾		1,356,293	A	$0	1,356,293	I	By CDDS 2.0, LLC
Common Stock	03/24/2026		G⁽²⁾		7,392	A	$0	1,363,685	I	By CDDS 2.0, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents 1,356,293 shares of Common Stock transferred from CD Financial, LLC, a Florida limited liability company, to CDDS 2.0, LLC, a Florida limited liability company controlled by the Reporting Person.

2. Represents 7,392 shares of Common Stock transferred from the Carl DeSantis Revocable Trust to CDDS 2.0, LLC, a Florida limited liability company controlled by the Reporting Person.

	/s/ Damon DeSantis	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Damon DeSantis report for INBP?

Damon DeSantis reported bona fide gift transfers involving 1,363,685 shares of INTEGRATED BIOPHARMA INC Common Stock. These were non-cash gifts at $0.00 per share, recorded as indirect holdings through CDDS 2.0, LLC that he controls.

How many INTEGRATED BIOPHARMA INC (INBP) shares were involved in the gifts?

A total of 1,363,685 Common Stock shares were involved. One transfer covered 1,356,293 shares and another covered 7,392 shares, both moved to CDDS 2.0, LLC, which is controlled by Damon DeSantis and reported as his indirect ownership.

Were the INBP insider transactions open-market buys or sells?

No, the INBP insider transactions were not open-market buys or sells. They were coded as “G” for bona fide gifts, with a per-share price of $0.00, reflecting non-cash transfers rather than market purchases or sales of the stock.

Who now holds the gifted INBP shares reported by Damon DeSantis?

The gifted INBP shares are now held by CDDS 2.0, LLC. Footnotes explain that shares came from CD Financial, LLC and the Carl DeSantis Revocable Trust into CDDS 2.0, LLC, a Florida limited liability company controlled by Damon DeSantis.

What is Damon DeSantis’ indirect INBP ownership after these gifts?

After these reported gift transfers, Damon DeSantis indirectly owns 1,363,685 INTEGRATED BIOPHARMA INC Common Stock shares. This entire position is held through CDDS 2.0, LLC, which the filing describes as a Florida limited liability company he controls.

How are the INBP gift transactions classified in the Form 4 summary?

In the Form 4 summary, the INBP transactions are classified as two gift dispositions. The transactionSummary lists two gifts totaling 1,363,685 shares, with no buys, sells, or derivative exercises, and net buy-sell activity characterized as neutral overall.